Immuno-oncologyFortvita Biologics and Innovent Biologics disclose new bispecific ADCs targeting EGFR and HGFRFortvita Biologics Inc. and Innovent Biologics (Hangzhou) Co. Ltd. have patented bispecific antibody-drug conjugates (ADCs) comprising a bispecific humanized monoclonal antibody targeting EGFR and hepatocyte growth factor receptors (HGFR; MET) linked to cytotoxic drugs reported to be useful for the treatment of cancer.